Adverum Biotechnologies Inc (ADVM)

$4.36 +0.10 (2.35%)
Market Cap 96.26M
Revenue (ttm) 1.00M
Net Income (ttm) -130.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13,093.00%
Debt to Equity Ratio 0.00
Volume 1,023,000
Avg Vol 670,538
Day's Range N/A - N/A
Shares Out 22.08M
Stochastic %K 95%
Beta 0.87
Analysts Sell
Price Target $4.90

Company Profile

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a f...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 656 9323
Fax: 650 649 1995
Website: adverum.com
Address:
100 Cardinal Way, Redwood City, United States
CoffeeRocks
CoffeeRocks May. 7 at 6:32 PM
$ADVM $BTAI $CODX $TPST CODX 2$ running 🏃‍♂️
0 ¡ Reply
CoffeeRocks
CoffeeRocks May. 7 at 4:03 PM
$BTAI $ADVM $TPST $CODX Phase 3 SERENITY At Home data is an absolute monster. They tracked over 2,400 agitation episodes. For severe agitation, complete resolution hit 61% for BXCL501 versus just 18% for placebo with a p value of <0.0001. Overall resolution was 50% versus 33% (p < 0.0001). The efficacy is undeniable. This is an already approved drug expanding into a massive 86M episode market. PDUFA is locked for Nov 14. The science is completely de risked. Once management clears the financial overhang, there is zero resistance left. Loading up while the crowd is distracted.
0 ¡ Reply
CoffeeRocks
CoffeeRocks May. 7 at 1:11 AM
$BTAI$CODX $TPST $ADVM Phase 3 SERENITY At Home data is an absolute monster. They tracked over 2,400 agitation episodes. For severe agitation, complete resolution hit 61% for BXCL501 versus just 18% for placebo with a p value of <0.0001. Overall resolution was 50% versus 33% (p < 0.0001). The efficacy is undeniable. This is an already approved drug expanding into a massive 86M episode market. PDUFA is locked for Nov 14. The science is completely de risked. Once management clears the financial overhang, there is zero resistance left. Loading up while the crowd is distracted.
0 ¡ Reply
gata2016
gata2016 Mar. 23 at 7:42 PM
$CABA Book it. "Yes, it is highly likely—almost standard practice—for a biotechnology company to schedule a conference call, webcast, or investor event to release positive clinical trial data. In RESET-MG, data will be presented in an oral presentation at 1:24 p.m. CDT on Monday, April 20, 2026" $CTNM $SANA $ADVM
4 ¡ Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 4:01 PM
$ADVM Outstanding article that hits the mark on ADVM's current state. So if you want to refresh your ADVM insights or learn about ADVM from scratch, this is a must read. https://everyticker.com/quote/ADVM/analysis/adverum-biotechnologies-gene-therapy-s-shot-at-wet-amd-fueled-by-data-facing-funding-headwinds-advm
0 ¡ Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 9:53 AM
$ADVM RSI: 59.32, MACD: 0.0018 Vol: 0.08, MA20: 4.22, MA50: 4.41 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 ¡ Reply
amswear13
amswear13 Jan. 22 at 3:07 PM
$ADVM
0 ¡ Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 3:32 PM
$ADVM RSI: 59.32, MACD: 0.0018 Vol: 0.08, MA20: 4.22, MA50: 4.41 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 ¡ Reply
TheHemisphereH
TheHemisphereH Dec. 25 at 2:55 PM
$ADVM The investment case increasingly rests on operational credibility rather than long‑range promises. Competitive differentiation needs clearer proof points. A series of confirmed wins might reduce the required risk premium. Execution precision will determine whether this evolves or stalls.
0 ¡ Reply
TwongStocks
TwongStocks Dec. 9 at 8:35 PM
$ADVM Equity Corporate Actions Alert #2025 - 666 (UPDATED: Merger Closed) Information Regarding the Tender Offer of Adverum Biotechnologies, Inc. (ADVM) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-666
0 ¡ Reply
Latest News on ADVM
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

Dec 9, 2025, 8:28 AM EST - 5 months ago

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

LLY

Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly

Dec 1, 2025, 7:00 AM EST - 5 months ago

Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly

Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM

Oct 25, 2025, 11:41 AM EDT - 7 months ago

Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM

LLY

Eli Lilly to buy gene therapy developer Adverum in about $262 million deal

Oct 24, 2025, 10:11 AM EDT - 7 months ago

Eli Lilly to buy gene therapy developer Adverum in about $262 million deal

LLY

Lilly to Acquire Adverum Biotechnologies

Oct 24, 2025, 8:30 AM EDT - 7 months ago

Lilly to Acquire Adverum Biotechnologies

LLY

Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration

Sep 22, 2025, 8:00 AM EDT - 8 months ago

Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 5, 2025, 4:01 PM EDT - 8 months ago

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights

Aug 12, 2025, 7:00 AM EDT - 9 months ago

Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights

Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 4:01 PM EDT - 10 months ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

May 14, 2025, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 4, 2025, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Mar 3, 2025, 4:01 PM EST - 1 year ago

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 20, 2024, 4:05 PM EST - 1 year ago

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Nov 15, 2024, 4:05 PM EST - 1 year ago

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Nov 4, 2024, 4:39 PM EST - 1 year ago

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Jul 17, 2024, 2:45 AM EDT - 1 year ago

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

May 9, 2024, 4:05 PM EDT - 2 years ago

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

May 3, 2024, 8:00 AM EDT - 2 years ago

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Apr 25, 2024, 4:05 PM EDT - 2 years ago

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Mar 18, 2024, 4:05 PM EDT - 2 years ago

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 4:05 PM EST - 2 years ago

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 12, 2024, 8:00 AM EST - 2 years ago

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

Feb 8, 2024, 7:00 AM EST - 2 years ago

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

CoffeeRocks
CoffeeRocks May. 7 at 6:32 PM
$ADVM $BTAI $CODX $TPST CODX 2$ running 🏃‍♂️
0 ¡ Reply
CoffeeRocks
CoffeeRocks May. 7 at 4:03 PM
$BTAI $ADVM $TPST $CODX Phase 3 SERENITY At Home data is an absolute monster. They tracked over 2,400 agitation episodes. For severe agitation, complete resolution hit 61% for BXCL501 versus just 18% for placebo with a p value of <0.0001. Overall resolution was 50% versus 33% (p < 0.0001). The efficacy is undeniable. This is an already approved drug expanding into a massive 86M episode market. PDUFA is locked for Nov 14. The science is completely de risked. Once management clears the financial overhang, there is zero resistance left. Loading up while the crowd is distracted.
0 ¡ Reply
CoffeeRocks
CoffeeRocks May. 7 at 1:11 AM
$BTAI$CODX $TPST $ADVM Phase 3 SERENITY At Home data is an absolute monster. They tracked over 2,400 agitation episodes. For severe agitation, complete resolution hit 61% for BXCL501 versus just 18% for placebo with a p value of <0.0001. Overall resolution was 50% versus 33% (p < 0.0001). The efficacy is undeniable. This is an already approved drug expanding into a massive 86M episode market. PDUFA is locked for Nov 14. The science is completely de risked. Once management clears the financial overhang, there is zero resistance left. Loading up while the crowd is distracted.
0 ¡ Reply
gata2016
gata2016 Mar. 23 at 7:42 PM
$CABA Book it. "Yes, it is highly likely—almost standard practice—for a biotechnology company to schedule a conference call, webcast, or investor event to release positive clinical trial data. In RESET-MG, data will be presented in an oral presentation at 1:24 p.m. CDT on Monday, April 20, 2026" $CTNM $SANA $ADVM
4 ¡ Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 4:01 PM
$ADVM Outstanding article that hits the mark on ADVM's current state. So if you want to refresh your ADVM insights or learn about ADVM from scratch, this is a must read. https://everyticker.com/quote/ADVM/analysis/adverum-biotechnologies-gene-therapy-s-shot-at-wet-amd-fueled-by-data-facing-funding-headwinds-advm
0 ¡ Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 9:53 AM
$ADVM RSI: 59.32, MACD: 0.0018 Vol: 0.08, MA20: 4.22, MA50: 4.41 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 ¡ Reply
amswear13
amswear13 Jan. 22 at 3:07 PM
$ADVM
0 ¡ Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 3:32 PM
$ADVM RSI: 59.32, MACD: 0.0018 Vol: 0.08, MA20: 4.22, MA50: 4.41 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 ¡ Reply
TheHemisphereH
TheHemisphereH Dec. 25 at 2:55 PM
$ADVM The investment case increasingly rests on operational credibility rather than long‑range promises. Competitive differentiation needs clearer proof points. A series of confirmed wins might reduce the required risk premium. Execution precision will determine whether this evolves or stalls.
0 ¡ Reply
TwongStocks
TwongStocks Dec. 9 at 8:35 PM
$ADVM Equity Corporate Actions Alert #2025 - 666 (UPDATED: Merger Closed) Information Regarding the Tender Offer of Adverum Biotechnologies, Inc. (ADVM) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-666
0 ¡ Reply
Universaal
Universaal Dec. 9 at 4:55 PM
$PRQR lily bought $ADVM
0 ¡ Reply
Mirandiiie
Mirandiiie Dec. 9 at 4:41 PM
$ADVM What happens to the shares for those who didn’t tender? Only 65% were tendered… Do they get converted into cash or Eli Lilly shares?
2 ¡ Reply
AZOZ
AZOZ Dec. 9 at 12:36 PM
$ADVM Insider activity
1 ¡ Reply
FreeBeerTomorrow
FreeBeerTomorrow Dec. 9 at 8:30 AM
$ADVM ADVM The halt was related to the pending acquisition of Adverum Biotechnologies (ADVM) by Eli Lilly and Company. Here are the details of the offer by Eli Lilly and Company to acquire Adverum Biotechnologies, Inc. (ADVM): ​💰 Acquisition Terms ​The total potential value of the transaction is up to $12.47 per share, structured as follows: Component Value Per Share Type Details Upfront Cash Payment $3.56 Cash Paid upon the closing of the tender offer. This gives stockholders immediate liquidity. Contingent Value Right (CVR) Up to $8.91
1 ¡ Reply
CEOBuysDisclosures
CEOBuysDisclosures Dec. 9 at 4:50 AM
$ADVM CEO purchased 128,699 shares at $4.30 for a total of $553,917. Fischer Laurent now owns 201,513 shares. https://ceo-buys.com
0 ¡ Reply
AlertsAndNews
AlertsAndNews Dec. 9 at 3:35 AM
$ADVM Multiple insider buys here. ADVM Adverum Biotechnologies, Inc.: Laurent Fischer (Director, CEO, President) Buys 128,699 Shares @ Avg Price $4.30 – Form 4 ADVM Adverum Biotechnologies, Inc.: Peter Soparkar (Chief Operating Officer) Buys 50,000 Shares @ Avg Price $4.22 – Form 4
0 ¡ Reply
TwongStocks
TwongStocks Dec. 9 at 1:27 AM
$ADVM Equity Corporate Actions Alert #2025 - 666 Information Regarding the Tender Offer of Adverum Biotechnologies, Inc. (ADVM) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-666 The tender offer by Eli Lilly and Company. ($LLY) to acquire all of the outstanding common stock of Adverum Biotechnologies, Inc. (ADVM) is scheduled to expire one minute after 11:59 p.m. ET, on December 8, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on December 9, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on December 8, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (December 9th) and will be suspended effective December 10, 2025. ADVM shareholders will receive $3.56 and a CVR for each share held at closing.
0 ¡ Reply
RJLeonii
RJLeonii Dec. 5 at 3:27 PM
$ADVM If you look at time value of money, CVR should be worth closer to 1.25 today. Thats why price targets are currently set at 5
0 ¡ Reply
fantastex
fantastex Dec. 1 at 6:25 PM
$ADVM gonna fall like a rock tò sub 3.
1 ¡ Reply
Kingcrab3333
Kingcrab3333 Nov. 17 at 11:26 PM
$ADVM
0 ¡ Reply